The debut of troglitazone, a potent insulin-sensitizing agent, marked a significant chapter in the treatment of type 2 diabetes. However, its discontinuation from the market due to severe hepatotoxicity spurred https://oisixwxr687816.activoblog.com/51193552/troglitazone-and-related-tzds-a-relative-overview